These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34331706)

  • 1. "Real world" eligibility for aducanumab.
    Canevelli M; Rossi PD; Astrone P; Consorti E; Vanacore N; Cesari M
    J Am Geriatr Soc; 2021 Oct; 69(10):2995-2998. PubMed ID: 34331706
    [No Abstract]   [Full Text] [Related]  

  • 2. "Real-world" eligibility for aducanumab depends on clinical setting and patients' journey.
    Padovani A; Caratozzolo S; Rozzini L; Pilotto A; Benussi A; Tedeschi G
    J Am Geriatr Soc; 2022 Feb; 70(2):626-628. PubMed ID: 34750815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aducanumab and the "post-amyloid" era of Alzheimer research?
    Musiek ES; Bennett DA
    Neuron; 2021 Oct; 109(19):3045-3047. PubMed ID: 34582783
    [No Abstract]   [Full Text] [Related]  

  • 4. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
    Zissimopoulos J; Jacobson M; Chen Y; Borson S
    JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Problem of Aducanumab for the Treatment of Alzheimer Disease.
    Alexander GC; Karlawish J
    Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642
    [No Abstract]   [Full Text] [Related]  

  • 6. Aducanumab and the Business of Alzheimer Disease-Some Choice.
    Karlawish J
    JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302
    [No Abstract]   [Full Text] [Related]  

  • 7. Alzheimer disease and aducanumab: adjusting our approach.
    Selkoe DJ
    Nat Rev Neurol; 2019 Jul; 15(7):365-366. PubMed ID: 31138932
    [No Abstract]   [Full Text] [Related]  

  • 8. Aducanumab for Alzheimer's disease?
    Walsh S; Merrick R; Milne R; Brayne C
    BMJ; 2021 Jul; 374():n1682. PubMed ID: 34226181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?
    Hershey LA; Tarawneh R
    Neurology; 2021 Sep; 97(11):517-518. PubMed ID: 34233940
    [No Abstract]   [Full Text] [Related]  

  • 10. Aducanumab: What about the Patient?
    Petersen RC
    Ann Neurol; 2021 Sep; 90(3):334-335. PubMed ID: 34322904
    [No Abstract]   [Full Text] [Related]  

  • 11. Aducanumab and the FDA - where are we now?
    Fillit H; Green A
    Nat Rev Neurol; 2021 Mar; 17(3):129-130. PubMed ID: 33442064
    [No Abstract]   [Full Text] [Related]  

  • 12. Aducanumab: look before leaping.
    Perlmutter JS
    Nat Med; 2021 Sep; 27(9):1499. PubMed ID: 34413517
    [No Abstract]   [Full Text] [Related]  

  • 13. Should Canadian patients look forward to aducanumab for Alzheimer disease?
    Watt JA; Marple R; Hemmelgarn B; Straus SE
    CMAJ; 2021 Sep; 193(36):E1430-E1431. PubMed ID: 34518345
    [No Abstract]   [Full Text] [Related]  

  • 14. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
    Manly JJ; Glymour MM
    JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
    [No Abstract]   [Full Text] [Related]  

  • 15. Aducanumab, amyloid, and culture wars.
    Iliffe S; Manthorpe J
    BMJ; 2021 Aug; 374():n2038. PubMed ID: 34413026
    [No Abstract]   [Full Text] [Related]  

  • 16. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
    Dal-Ré R
    Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Questions EMERGE as Biogen claims aducanumab turnaround.
    Howard R; Liu KY
    Nat Rev Neurol; 2020 Feb; 16(2):63-64. PubMed ID: 31784690
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial: How Will Aducanumab Approval Impact AD Research?
    Weiner MW; Aisen PS; Beckett LA; Green RC; Jagust W; Morris JC; Okonkwo O; Perrin RJ; Petersen RC; Rivera Mindt M; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ
    J Prev Alzheimers Dis; 2021; 8(4):391-392. PubMed ID: 34585209
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    Alexander GC; Emerson S; Kesselheim AS
    JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
    [No Abstract]   [Full Text] [Related]  

  • 20. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.